Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
55 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Adaptive Biotechnologies Corporation’s names, not what it holds today.
Patents granted
55
55 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 1 in 2024 and 2 in 2023
Applications published
63
5 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology13
Computer technology4
Pharmaceuticals2
Medical technology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Adaptive Biotechnologies Corporation its own name
US, as the owner printed on each patent
8 publishedAdaptive Biotechnologies Corporation its own name
named as the applicant on its applications, in US
55 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 30, 2025 | 12,428,682 | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing | Biotechnology | Adaptive Biotechnologies Corporation |
| Jul 8, 2025 | 12,351,872 | Determining antigen-specific T-cells | Biotechnology | Adaptive Biotechnologies Corporation |
| Apr 1, 2025 | 12,266,425 | T cell receptor sequences diagnostic for COVID-19 and related compositions | Medical technology | Adaptive Biotechnologies Corporation |
| Apr 1, 2025 | 12,263,179 | Lyme disease-associated T cell receptor-related methods | Pharmaceuticals | Adaptive Biotechnologies Corporation |
| Jan 28, 2025 | 12,209,282 | Monitoring health and disease status using clonotype profiles | Biotechnology | Adaptive Biotechnologies Corporation |
| Jan 14, 2025 | 12,195,795 | Synthetic strands for nucleic acid sequencing and related methods and systems | Computer technology | Adaptive Biotechnologies Corporation |
| Oct 1, 2024 | 12,104,211 | Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization | Computer technology | Adaptive Biotechnologies Corporation |
| Oct 3, 2023 | 11,773,442 | Method for studying V(D)J combinatory diversity | Biotechnology | Adaptive Biotechnologies Corporation |
| Jul 25, 2023 | 11,708,605 | Synthetic strands for nucleic acid sequencing and related methods and systems | Computer technology | Adaptive Biotechnologies Corporation |
| Jul 19, 2022 | 11,390,921 | Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs) | Biotechnology | Adaptive Biotechnologies Corporation |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Apr 24, 2025 | 2025/0129420 | Monitoring Health and Disease Status Using Clonotype Profiles | Biotechnology | Adaptive Biotechnologies Corporation |
| Mar 27, 2025 | 2025/0101531 | Immunocompetence Assessment by Adaptive Immune Receptor Diversity and Clonality Characterization | Biotechnology | Adaptive Biotechnologies Corporation |
| Mar 6, 2025 | 2025/0074966 | AGENTS AND METHODS FOR PREVENTING OR INHIBITING ADAPTIVE IMMUNE RESPONSES ASSOCIATED WITH MULTIPLE SCLEROSIS | Medical technology | Adaptive Biotechnologies Corporation |
| Feb 13, 2025 | 2025/0049910 | Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2 | Pharmaceuticals | Adaptive Biotechnologies Corporation |
| Feb 6, 2025 | 2025/0043272 | Uniquely Tagged Rearranged Adaptive Immune Receptor Genes in a Complex Gene Set | Biotechnology | Adaptive Biotechnologies Corporation |
| Apr 4, 2024 | 2024/0112754 | Crohn's Disease-Associated T Cell Receptor-Related Methods | Medical technology | Adaptive Biotechnologies Corporation |
| Feb 15, 2024 | 2024/0052411 | Synthetic Strands for Nucleic Acid Sequencing and Related Methods and Systems | Computer technology | Adaptive Biotechnologies Corporation · patent 12,195,795 granted from it |
| Nov 30, 2023 | 2023/0382979 | ANTI-SARS-COV-2 ANTIGEN ANTIBODIES AND RELATED COMPOSITIONS AND METHODS | Biotechnology | Adaptive Biotechnologies Corporation |
| Feb 9, 2023 | 2023/0042101 | Determining WT-1-Specific T Cells and WT-1 Specific T Cell Receptors (TCRS) | Biotechnology | Adaptive Biotechnologies Corporation |
| Sep 22, 2022 | 2022/0298575 | Immunocompetence Assessment by Adaptive Immune Receptor Diversity and Clonality Characterization | Biotechnology | Adaptive Biotechnologies Corporation · patent 12,104,211 granted from it |
What it applied for, 2024 to 2025: Biotechnology 3 · Medical technology 2 · Computer technology 1 · Pharmaceuticals 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.